OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer

  • Authors:
    • Jonathan Tammela
    • Akiko Uenaka
    • Toshiro Ono
    • Yuji Noguchi
    • Achim A. Jungbluth
    • Paulette Mhawech-Fauceglia
    • Feng Qian
    • Sally Schneider
    • Sameer Sharma
    • Deborah Driscoll
    • Shashikant Lele
    • Lloyd J. Old
    • Eiichi Nakayama
    • Kunle Odunsi
  • View Affiliations

  • Published online on: October 1, 2006     https://doi.org/10.3892/ijo.29.4.903
  • Pages: 903-910
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

OY-TES-1 is a novel target that belongs to the family of ‘cancer/testis’ (CT) antigens. Our goal was to examine the expression and immunogenicity of OY-TES-1 in epithelial ovarian cancer (EOC) to determine its potential as a target for vaccine therapy. OY-TES-1 expression was determined by one-step reverse transcriptase PCR on 100 EOC samples, 5 EOC cell lines, and a panel of normal tissues. Immunohistochemistry (IHC) was performed on the same panel of EOC tissues. Sera from a sub-group of patients were tested for OY-TES-1 antibody by ELISA. Thymus and leukocytes were weakly positive for OY-TES-1 while the remaining 5 normal tissues were negative. Expression of OY-TES-1 by either RT-PCR and/or IHC was demonstrable in 69/100 (69%) tumors. Humoral immunity to OY-TES-1 was demonstrated in 1/10 (10%) serum samples from patients whose tumors expressed the antigen. The median follow-up of the patient population was 34 months. There was no correlation between antigen expression and stage, grade, histology and survival. OY-TES-1 is expressed in 69% of patients with EOC, is absent from normal ovarian tissue, and a proportion of patients show evidence of a specific humoral immune response. These findings make OY-TES-1 an attractive target for antigen-specific immunotherapy in EOC.

Related Articles

Journal Cover

October 2006
Volume 29 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tammela, J., Uenaka, A., Ono, T., Noguchi, Y., Jungbluth, A.A., Mhawech-Fauceglia, P. ... Odunsi, K. (2006). OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. International Journal of Oncology, 29, 903-910. https://doi.org/10.3892/ijo.29.4.903
MLA
Tammela, J., Uenaka, A., Ono, T., Noguchi, Y., Jungbluth, A. A., Mhawech-Fauceglia, P., Qian, F., Schneider, S., Sharma, S., Driscoll, D., Lele, S., Old, L. J., Nakayama, E., Odunsi, K."OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer". International Journal of Oncology 29.4 (2006): 903-910.
Chicago
Tammela, J., Uenaka, A., Ono, T., Noguchi, Y., Jungbluth, A. A., Mhawech-Fauceglia, P., Qian, F., Schneider, S., Sharma, S., Driscoll, D., Lele, S., Old, L. J., Nakayama, E., Odunsi, K."OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer". International Journal of Oncology 29, no. 4 (2006): 903-910. https://doi.org/10.3892/ijo.29.4.903